Please ensure Javascript is enabled for purposes of website accessibility

Why Halozyme Therapeutics, Inc. Jumped 15.6% in January

By Brian Feroldi - Feb 2, 2017 at 9:24AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares rose in response to the release of upbeat clinical data from an important phase 2 study.

Man putting money into his pocket

Image source: Getty Images.

What happened

Shares of Halozyme Therapeutics (HALO -0.69%), a commercial-stage biopharma, rose by more than 15% in January, according to data from S&P Global Market Intelligence:

HALO Chart

HALO data by YCharts.

So what

Halozyme kicked off the new year by announcing top-line data from its phase 2 HALO 202 study. This trial was studying Halozyme's PEGPH20 in combination with Celgene's Abraxane and Eli Lilly's Gemzar in treating patients with stage 4 pancreatic cancer.

Data from the study showed that the combination of drugs succeeded in meeting its primary endpoints, which were defined as a statistically significant improvement in progression-free survival (PFS) and a reduction in thromboembolic events. Management was particularly excited to point out that patients who displayed high levels of hyaluronan and took PEGPH20 showed a median progression-free survival rate of 8.6 months, which is a 91% improvement over the 4.5 months observed in the group of patients who did not receive PEGPH20.

The company is currently running a phase 3 clinical trial studying the combination of drugs at more than 160 sites around the world.

Beyond the clinical update, Halozyme also provided investors with guidance for 2017 at the 2017 J.P. Morgan Healthcare Conference. Here's a review of what management expects to happen in the year ahead:

  • Revenue of $115 million to $130 million
  • Operating expenses of $240 million to $250 million
  • Year-end cash balance of $100 million to $110 million

These numbers suggest that Halozyme's revenue is going to decline year over year. However, management quickly pointed out that the decline is mostly because of $20 million in reimbursed research-and-development payments in 2016 that are not expected to repeat in 2017. It doesn't include any potential revenue from new partnerships or collaborations either.

Operating expenses are expected to remain elevated in order to advance the company's pipeline, but they should be roughly flat year over year.

While the company's financial guidance was disappointing, the upbeat clinical news was strong enough to allow shares to rally in January.

Now what

Halozyme's clinical data was exciting, but it wasn't exactly bulletproof. In fact, some critics pointed out that the strong PFS data was only achieved in the subset of patients who displayed high levels of hyaluronan. That amps up the pressure on the company to deliver knockout results when it reports data from its larger phase 3 trial.

Unfortunately, investors will have some waiting to do before they know more. Data from the HALO 301 study isn't expected to be available until late 2018. In the meantime, shares are likely to remain volatile. Shareholders should continue to brace themselves for a bumpy ride.

Brian Feroldi owns shares of Celgene. The Motley Fool owns shares of and recommends Celgene. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Halozyme Therapeutics, Inc. Stock Quote
Halozyme Therapeutics, Inc.
$43.11 (-0.69%) $0.30

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.